Thymosins in Health and Disease: First International Conference, Volume 1112

1. Contributions from all over: widely-distributed residues in thymosin β4 affect the kinetics and stability of actin binding: Daniel Safer.

2. The β-thymosin engima: Helen L. Yin.

3. The interaction of the C-terminal half of thymosin β4 with actin: Robert C. Robinson.

4. Evolution of the actin-sequestering function in β-thymosins and modular β-thymosin repeat proteins: Marie-France Carlier.

5. Thymosin β4: actin regulation and more: Elena G. Yarmola.

6. The thymosin fold among cytoskeletal proteins: multifunctionality and structure: Roberto Dominguez.

Part II: Wound Healing, Inflammation, and Fibrosis:.

7. Unexpected findings in mice overexpressing thymosin β4: Hynda Kleinman.

8. Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin β4: Czeslow S. Cierniewski.

9. Thymosin β4 and the eye: I can see clearly now the pain is gone: Gabe Sosne.

10. In vivo detection of thymosins via mass spectrometric proteomics an ultrafiltration sampling: the role of in vivo secreted-thymosins in skin biology: Chun-Ming (Eric) Huang.

11. Airway disease and sputum: the role of DNA and actin polymers: Bruce Rubin.

12. Liver cirrhosis: a reversible process?: Marcos Rojkind.

Part III: Cardiovascular Protection, Neuroplasticity, Stem Cells Repair, and Regeneration:.

13. Cardiac protection and angiogenesis induced by thymosin β4: Deepak Srivistava.

14. Thymosin β4: the potential for neovascular therapy in the injured adult heart: Paul R. Riley.

15. Post-translational regulation of β-thymosin repeat protein: contribution to intrinsic cellular excitability: Terry Crow.

16. Prothymosin α in relation to chromatin decondensation and the role of β-thymosins in synaptic plasticity: Jaime Gomez-Marquez.

17. Thymosin β4 as a protective agent in the nervous system and the effects of its overexpression/ablation in neuronal and tumoral stem cells: Daniela Merlo.

18. Emerging multipotent roles of thymosin β in the development and regeneration of the nervous system: Woong Sun.

Part IV: Immunopharmocology, Pharmacogenomics, and Combination Therapies:.

19. Thymosin alpha 1 from bench to bedside: Enrico Garaci.

20. Immunopharmacology of thymosin α1: Paul Naylor.

21. IRX-3: A novel biologic to reverse immune suppression: John Hadden.

22. Clinical experiences with thimosins in influenza: William Ershler.

23. IFN-α and novel strategies of combination therapy of cancer: Filippo Belardelli.

24. Combination Trials with thymosin alpha 1 in hepatitis B and C: Guido Rasi.

Part V: Molecular Markers, Signaling, and Diagnostics for Cancer and Infectious Diseases:.

25. Thymosin α1 as a chemopreventive agent in breast and lung cancer: Terry Moody.

26. Characterization of a peptide component of thymosin fraction-5 manifesting cytostatic properties in HL-60 human promyelocytic leukemia cells: Brian Spangelo.

27. Cellular distribution of thymosin β4 in tumors: Lars-Inge Larsson.

28. Anti-HIV-1 activity of both thymosin β4 and prothymosin α: Arevik Mosoian.

29. Thymosin α1: an endogenous regulator of inflammation and tolerance in antimicrobial immunity and autoimmunity: Luigina Romani.

30. Activation of signal pathways by thymosin α1: Wen-ming Chu.

Part VI: Clinical Applications of Thymosin a1 and Thymosin b4:.

31. Issues in pharmaceutical development of thymosin α1 from preclinical studies through marketing: Cynthia Tuthill.

32. Clinical experience with the role of thymosin alpha 1 in hepatitis B and C: Vinod K. Rustgi.

33. European Phase III, Randomized, Double Blind, Multicenter Study of Triple Therapy with Thymosin alpha 1 plus Pegylated Interferon alpha-2a plus Ribavirin in Non Responder Patients with Chronic Hepatitis C. Study Design and Preliminary Safety Data: Mario Rizzetto.

34. Development of Thymosin β4 for Ischemic Heart Disease: David Crockford.

35. β-thymosin and venous ulcers: clinical remarks on a European perspective, randomised study on safety, tolerabiilty, and enhancement on healing: Giorgio Guarnera.

36. Myocardial infarction markers in patients with acute limb ischaemia: Piotr Gutowski.

37. Thymosin β4 and epidermolysis bullosa: Jo-David Fine.

38. Chronic Cutaneous Wound Treatment: Pressure Ulcers – A Role for Thymosin β4: Mike Godschalk